Europe PMC

Background Psoriasis is frequently accompanied by depression. However, the role of specific symptom domains, including cognitive-affective and somatic symptoms, as well as potential metabolic mediators between psoriasis and depression, remains unclear.Methods We analyzed data from the National Health and Nutrition Examination Survey (NHANES, n = 14,964) and the Health and Retirement Study (HRS, n = 4364). Depressive symptoms were classified into cognitive-affective and somatic domains. Cross-sec

No abstract supplied.Weiterlesen

Background Psoriasis, a chronic autoimmune condition, can severely impact patients' well-being. It is characterized by erythema, thickening, and scaling of the skin. Plaque psoriasis, the most prevalent type, affects 80%-90% of psoriasis patients, ranging from localized to severe cases. Although corticosteroids are commonly used to treat psoriasis, prolonged use poses risks. Therefore, alternative therapies are needed. Roflumilast, a potent phosphodiesterase 4 inhibitor, is currently being consi

Introduction Psoriasis is a chronic inflammatory skin disease associated with significant physical and psychological burden. Tildrakizumab, an interleukin-23 p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe plaque psoriasis both in clinical trials and real-world setting. However, limited data are available on the impact of the effective treatment of psoriasis on the psychological health of patients. The aim of this study was to assess changes in psychological well-being, a

Abstract Objective To explore the clinical application value of Neutrophil extracellular traps (NETs) in evaluating psoriasis. Methods 2ml peripheral blood of 63 patients with psoriasis and 27 healthy controls were collected. Neutrophils were isolated by density gradient method, and the formation of NETs was observed by immunofluorescence staining. We then calculated the proportion and fluorescence intensity of NETs and analyzed their correlation with clinical classification, severity, and se

Psoriasis is a chronic, relapsing inflammatory skin disease. Topical treatments are the primary choice for up to 80% of psoriasis patients; however, their effectiveness is often limited by poor penetration into the skin. Nanocarriers represent a promising advancement in drug delivery systems by enhancing bioavailability and tissue penetration and reducing the frequency of dosing. This study conducted a narrative review and analyzed the characteristics of clinical trials registered on ClinicalTri

Abstract Background This study collected and analyzed clinical data from patients with psoriasis, developing and validating a risk prediction model for psoriasis relapse. The aim is to improve the efficiency and accuracy of early screening for psoriasis relapse in clinical practice and to provide a reference for implementing preventive measures. Objective To develop and validate a risk prediction model for psoriasis relapse. Methods A convenience sampling method was used to select 504 psoria

No abstract supplied.Weiterlesen

Introduction Interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are advanced therapeutic options for moderate-to-severe psoriasis. In real-world settings, biologic persistence is commonly used as a proxy for effectiveness and safety, and a treatment-free status following biologic discontinuation may provide insights into disease remission. This study aimed to assess persistence and treatment-free status for IL-17i versus IL-23i among biologic-naïve patients with psoriasis

Guselkumab (TREMFYA®) is a fully human IgG1λ monoclonal antibody developed by Johnson & Johnson to selectively target the p19 subunit of interleukin (IL)-23, a cytokine that plays a key role in various immune-mediated inflammatory diseases. Guselkumab is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment of adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately-to-severely active ulcerative colitis and Crohn

Dear Editor, Psoriasis is a chronic, immune-mediated inflammatory dermatosis that affects approximately 3% of the adult population and exerts a substantial impact on health-related quality of life (QoL). The plaque-type variant is the most prevalent clinical form, typically involving the trunk and limbs. The anatomical distribution of psoriatic lesions has been demonstrated to play a critical role in shaping the disease burden, with visible and exposed areas contributing disproportionately to ps

Psoriasis, long thought to be a chronic immune-mediated dermatological disease, is now being reclassified as a systemic inflammatory disease with substantial metabolic and hepatic complications. Psoriasis affects approximately 2-3% of global population and is associated with up to 50% risk of systemic comorbidities. This mini-review examines the evolving understanding of psoriasis pathogenesis, focusing on the interaction of immunological dysregulation, keratinocyte hyperproliferation, and syste

Aim Risankizumab is a high-cost biologic treatment for chronic plaque psoriasis, an immune-mediated inflammatory disease presenting with painful red scaly skin lesions. Inter-individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (PK/PD) model to characterise the relationship between risankizumab exposure and treatment response.Methods A sequential population PK/PD model was develop

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background Narrowband ultraviolet B (NB-UVB) phototherapy is a well-established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited.Objectives To evaluate treatment response, relapse patterns, and predictors of relapse-free duration in pediatric psoriasis patients treated with NB-UVB phototherapy, with a particular focus on concomitant topical c

BACKGROUND Guttate psoriasis is a form of psoriasis that often occurs following infections and is most commonly triggered by group A Streptococcus. The link between streptococcal pharyngitis and the development of guttate psoriasis is well documented in younger populations; however, this presentation in older adults is less common. Additionally, older adult populations can have multiple comorbidities that could influence the development and clinical course of guttate psoriasis. CASE REPORT We re

Importance Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.Objective To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.Design, setting, and participants The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years' total treatment). Patients initially received bimekizumab or secukinumab. A

Objective To describe the comorbidity profile in patients with moderate-to-severe psoriasis treated with biologics and their association with clinical phenotype and therapeutic choice.Material and methods This was an observational, cross-sectional, single-center study conducted at the Lozano Blesa University Clinical Hospital (Zaragoza, Spain). Consecutive patients with moderate-to-severe psoriasis receiving biologic treatment were included. Data were collected during the Dermatology consultatio

Background Nail involvement is common in psoriasis, yet objective and non-invasive biomarkers of nail disease activity are limited. The biochemical composition of the nail plate may reflect local pathophysiological changes and could provide measurable indicators of disease severity.Objective To compare the nail biochemical composition between psoriatic patients with and without nail involvement, and to examine its associations with nail severity.Methods In this case-control study, nail clippings

No abstract supplied.Weiterlesen

Introduction Human beta-defensin 2 (hBD-2) is an antimicrobial peptide upregulated by IL-17A and TNF-α, important in skin immunity and inflammation. While hBD-2 is elevated in psoriatic skin, its systemic expression and clinical significance remain unclear, particularly in psoriatic arthritis (PsA).Objectives To compare serum hBD-2 levels among patients with psoriasis vulgaris, PsA, and healthy controls, and to evaluate its correlation with disease severity and inflammatory markers.Methods This

Background Asthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.Methods Data from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic r

No abstract supplied.Weiterlesen

Psoriatic arthritis is a chronic inflammatory disease associated with psoriasis, and its diagnosis can be challenging owing to nonspecific symptoms, absence of reliable biomarkers, and occasional delay in skin manifestations. Herein, we report a case of psoriatic arthritis that initially presented as an acute finger inflammation mimicking infection. A 46-year-old woman developed sudden swelling and pain in the left ring finger during chemotherapy for cervical cancer. Based on the results of the